Global IVD Leaders - Mapping the Growth Share of 23 Companies

The In Vitro Diagnostics Growth-Share Matrix: Mapping 23 Global IVD Leaders Through China Headwinds and Oncology-Testing Breakouts

The global in vitro diagnostics (IVD) market is estimated at approximately $99.51 billion in 2025, growing at a 4.94% CAGR to roughly $126.6–$132.9 billion by 2031 — a synthesis of nine independently published third-party estimates whose unusually wide range reflects genuine scope-definition differences across publishers rather than any single authoritative figure.

Two patterns dominate this year's disclosures across the 23 companies profiled. First, China has become the single most-cited headwind in the entire sector — Bio-Rad, QuidelOrtho, QIAGEN, Sysmex, and Roche Diagnostics all independently flagged China-specific weakness (pricing reform, procurement policy, or order-timing disruption) in their most recent 2026 results, making it the clearest cross-company theme in this matrix. Second, oncology and molecular-testing specialists are posting the sector's standout growth, led by Natera's 38% Q2 2026 revenue surge on record Signatera cancer-testing volume and Illumina's raised guidance on accelerating clinical sequencing demand — a sharp contrast to the more modest, sometimes negative growth posted by several of the diversified, instrument-heavy incumbents navigating the same China and academic-funding pressures.

This briefing applies the growth-share framework to all 23 companies named in the underlying report, using only what each has disclosed in 2026 earnings releases, regulatory filings, and public statements.

Market Sizing Snapshot, 2025–2031

Source: Global In Vitro Diagnostics (IVD) Market Strategic Research Report, Market Research Reports Inc.

The Growth-Share Lens, Applied to IVD

Three dynamics define competitive position across the 23 majors profiled:

• Oncology and molecular/genomic testing — the report's clearest growth pocket, where liquid-biopsy and MRD (molecular residual disease) testing volumes are compounding at rates far outpacing the broader IVD market.
• China-exposed instrument and reagent sales — a genuinely bifurcated category this year, with pricing-reform and procurement-policy disruption cited independently by five separate companies.
• Legacy respiratory and infectious-disease testing — a mature, epidemiology-dependent category where year-over-year comparisons swing heavily based on respiratory-season severity rather than underlying structural demand.

Company-by-Company Positioning

Companies below are ordered by disclosed revenue, largest first. Each figure is the most recently reported quarterly, half-year, or full-year guidance figure, annualized where needed (×4 for a quarter, ×2 for a half-year), on a currency-as-reported basis converted to approximate USD. Where the report names a specific segment rather than the whole company (Roche Diagnostics), that segment's revenue is used. These are rough, single-period approximations for ordering purposes only.

1. Abbott Laboratories

Abbott Laboratories (~$50.4B annualized, whole company) posted Q2 2026 comparable sales growth of 8.4% company-wide, with its Diagnostics business benefiting from continued BinaxNOW and core lab testing demand alongside the broader company's electrophysiology and CGM momentum.

MRR's Take: Abbott's diversified diagnostics and testing franchise is a Cash Cow with genuine growth pockets — its scale across core lab, rapid, and molecular testing gives it a breadth few pure-play IVD competitors can match.

2. Thermo Fisher Scientific

Thermo Fisher Scientific (~$48.0B annualized) delivered Q2 2026 revenue of $11.99 billion, up 10%, and raised full-year 2026 guidance to $47.4–$48.1 billion, citing broad-based strengthening customer activity and strong pharma/biotech bioproduction demand, even as it completed a divestiture of its microbiology business expected to reduce 2026 revenue by roughly $200 million.

MRR's Take: Thermo Fisher's Laboratory Products and Biopharma Services segment is a clear Star, with the deliberate microbiology divestiture signaling active portfolio-sharpening away from a lower-growth IVD sub-category.

3. Danaher Corporation

Danaher Corporation (~$25.2B annualized) reported Q2 2026 revenue of $6.3 billion, up 5.5%, with Life Sciences posting its strongest quarter in several years and the $9.8 billion Masimo acquisition completed ahead of schedule; Danaher's historical water-quality diagnostics assets were spun into the separately traded Veralto Corporation in 2023, so the entity profiled here is now primarily a life sciences and diagnostics instruments company.

MRR's Take: Life Sciences, boosted by Masimo, is a Star; the broader Diagnostics segment is a stable Cash Cow.

4. Siemens Healthineers AG

Siemens Healthineers AG (~$25.0B annualized) cut fiscal 2026 revenue growth guidance to 3.5–4% from 4.5–5%, citing continued Diagnostics weakness tied to structural market rebasing in China, down roughly 40% from two years ago, even as Imaging and Precision Therapy performed in line with plan.

MRR's Take: Diagnostics, specifically its China-exposed business, is the clearest Dog in this matrix; the Imaging and Precision Therapy "Synergetic Core" remains a steady Cash Cow.

5. Becton Dickinson (BD)

Becton Dickinson (BD) (~$20.0B annualized) completed the spin-off of its former Biosciences and Diagnostic Solutions business, combined with Waters Corporation, on February 9, 2026, and reported Q3 fiscal 2026 "New BD" revenue of $5.0 billion, up 4.4%, with more than 90% of the retained portfolio growing at high-single-digit rates or better.

MRR's Take: Post-spinoff BD is a leaner Cash Cow-to-Star transition story, though this restructuring means BD's remaining diagnostics-adjacent exposure is now smaller and more concentrated than before.

6. Roche Diagnostics

Roche Diagnostics (~$16.8B annualized, segment) posted H1 2026 sales of CHF 6.7 billion, up 3% (up 6% excluding China's healthcare pricing reform impact), with pathology lab sales up 11%, driven by advanced staining and companion diagnostics growth of 24%.

MRR's Take: Roche's core lab and pathology businesses are Stars once China's disclosed, quantified policy headwind is excluded — the China effect here is regulatory, not a genuine demand problem.

7. Agilent Technologies

Agilent Technologies (~$7.5B annualized) delivered Q3 fiscal 2026 revenue of $1.88 billion, up 8.1% reported and 7.3% core, exceeding guidance, and raised full-year revenue guidance to $7.49–$7.51 billion, with pharma end-market growth of 12% driven by GLP-1-related demand and China growing 9% against a flat expectation.

MRR's Take: Agilent's Life Sciences and Diagnostics Markets group, up 11% in the quarter, is a Star; the company's continued China strength stands out as a genuine counter-example to the sector's broader China narrative.

8. Dexcom

Dexcom (~$5.2B annualized) reported Q2 2026 revenue of $1.31 billion, up 13%, raising full-year guidance to $5.18–$5.25 billion, with a CMS coverage decision for type 2 non-insulin continuous glucose monitoring now expected around mid-2027.

MRR's Take: Dexcom's core CGM franchise is a Star; the delayed CMS decision is a Question Mark on timing rather than likelihood of a significant addressable-market unlock.

9. Illumina

Illumina (~$4.6B annualized) reported Q2 2026 revenue of $1.16 billion, up 9.5%, and raised full-year 2026 revenue guidance to $4.60–$4.64 billion on accelerating clinical sequencing demand, with U.S./Canada clinical consumables growing above 20% even as research and applied consumables continued to decline.

MRR's Take: Clinical sequencing is a clear Star; the research and applied consumables business remains a Question Mark still awaiting a clearer academic-funding recovery.

10. bioMérieux

bioMérieux (~$4.25B annualized) reported H1 2026 sales of €1,965 million, down slightly year-over-year on weaker respiratory epidemiology, but with net income rising to €226 million on meaningful margin discipline; the company reaffirmed 2026 guidance of 3–5% organic sales growth after acquiring Day Zero Diagnostics in June 2025 and completing the Accellix acquisition for pharma quality control in Q1 2026.

MRR's Take: bioMérieux's non-respiratory GO•28 growth drivers, up 6% organically in H1, are a Star; its BIOFIRE respiratory panel franchise is a Cash Cow whose results swing meaningfully with epidemiology from year to year.

11. Hologic

Hologic (~$4.19B annualized, last public quarter) completed its $18.3 billion take-private acquisition by Blackstone and TPG on April 7, 2026, confirmed in the underlying report's own overview; its final public quarter showed revenue of $1.05 billion, up 2.5%.

MRR's Take: With Hologic now under private ownership, it sits outside this matrix's public-market growth-share framework — its women's-health diagnostics franchise was judged undervalued enough by its new owners to command a 46% premium.

12. Bruker Corporation

Bruker Corporation (~$3.55B annualized, FY guidance) returned to organic revenue growth in Q2 2026 with revenue of $838.5 million, up 5.2%, with Scientific Instruments bookings up 10% organically and semiconductor metrology and energy research orders both growing over 50%, even as the company recorded a $135 million non-cash goodwill impairment tied to its automation and spatial biology businesses.

MRR's Take: Bruker's semiconductor and deep-tech-linked analytical instruments are a Star; the impaired automation and spatial biology businesses are a disclosed Dog the company is actively writing down rather than continuing to fund at prior levels.

13. Exact Sciences

Exact Sciences (~$3.25B FY2025 revenue) grew full-year 2025 revenue 17.7% to $3.25 billion, and continued double-digit revenue growth into Q2 2026 on continued Cologuard and Cologuard Plus adoption alongside expanding precision oncology testing.

MRR's Take: The Cologuard screening franchise is a Star, still compounding well after 20 million cumulative tests, while newer blood-based colorectal and multi-cancer screening pipeline products are Question Marks with a credible path to becoming the next growth wave.

14. Sysmex Corporation

Sysmex Corporation (~$3.1B annualized, H1 FY2026) reported H1 net sales of ¥232.5 billion, down 4.1% year-over-year, with operating profit down 25.9% to ¥32.9 billion, driven by China cost-control policy pressure and a Japan core-system transition, prompting a downward full-year guidance revision.

MRR's Take: Sysmex's core hematology and immunodiagnostics franchise is a Cash Cow under real near-term pressure; the company's own guidance cut, tied explicitly to China policy and a one-time systems transition, places it among the more genuinely challenged names in this matrix for the period.

15. Natera

Natera (~$2.88B FY2026 guidance) delivered Q2 2026 revenue of $753 million, up 38%, with MRD (molecular residual disease) oncology testing volume up 56% to 283,000 tests, and raised full-year 2026 revenue guidance to $2.85–$2.91 billion — implying roughly 31% annual growth.

MRR's Take: Signatera and the broader oncology MRD franchise are the clearest Star in this entire matrix by growth rate, backed by a string of 2026 regulatory wins including FDA companion-diagnostic approval and Japanese PMDA clearance.

16. Revvity

Revvity (~$2.85B FY2026 guidance, pro forma) posted Q2 2026 pro forma revenue of $711 million, with Diagnostics revenue up 11% organically (reproductive health growing in the mid-teens) even as Life Sciences declined 3% organically on a 20% drop in its Signals software business; the company raised full-year organic growth guidance to 4–5% and is divesting its China immunodiagnostics business, expected to close by end of 2027.

MRR's Take: Diagnostics, especially reproductive health, is a clear Star; the Signals software decline and the China IDX divestiture together represent a Question Mark segment the company is actively resizing rather than continuing to defend.

17. Bio-Rad Laboratories

Bio-Rad Laboratories (~$2.6B annualized) reported Q2 2026 revenue of $651 million, essentially flat, with Clinical Diagnostics returning to modest growth (+2.6% reported) while Life Science declined 4.1% on continued academic-research softness and a roughly high-teens China decline; the company announced a restructuring targeting $30–35 million in annualized savings by 2027.

MRR's Take: Digital PCR, with instrument revenue up over 20%, is a Star within an otherwise Cash Cow Clinical Diagnostics base; Life Science is a Question Mark awaiting an academic-funding recovery.

18. QuidelOrtho Corporation

QuidelOrtho Corporation (~$2.56B FY2026 guidance) reported Q2 2026 revenue of $631 million, up 3% (up 6% excluding China), but sharply lowered full-year 2026 revenue guidance to $2.52–$2.60 billion from a prior $2.70–$2.75 billion, citing persistent China weakness tied to proposed IVD pricing guidelines and a more cautious respiratory-season outlook.

MRR's Take: QuidelOrtho's Labs and Point of Care businesses outside China are a genuine Star, up 9% and 5% respectively; China-specific revenue is the clearest, most sharply guided-down Dog disclosed by any company in this matrix.

19. Werfen

Werfen (~$2.4B, post-acquisition scale) is a privately held, family-controlled specialized diagnostics company whose revenues now exceed €2.2 billion following the completed acquisition of Immucor for approximately $2 billion, expanding its transfusion and transplant diagnostics leadership; the company has also divested its lower-margin medical device distribution businesses (Izasa Medical, Izasa Scientific, MC Medical) to Palex to sharpen its specialized diagnostics focus.

MRR's Take: Werfen's core hemostasis, transfusion, and specialized diagnostics franchise is a Star, and the deliberate divestiture of distribution businesses representing 7% of 2023 sales is a clear, disclosed example of portfolio-sharpening toward the highest-margin segment.

20. QIAGEN N.V.

QIAGEN N.V. (~$2.14B annualized) reported Q2 2026 net sales of $535 million, unchanged year-over-year, beating guidance for a roughly 2% decline, with growth pillars (Sample Technologies, QIAcuity, QIAGEN Digital Insights) up about 5% offsetting a significant, disclosed $35 million QuantiFERON revenue impact from reduced U.S. immigration testing demand.

MRR's Take: QIAGEN's Sample Technologies and digital PCR growth pillars are a Star; QuantiFERON, while still growing 1% despite the immigration-testing headwind, sits as a Cash Cow whose near-term trajectory is tied to a policy variable outside the company's control.

21. Seegene Inc.

Seegene Inc. (~$355M annualized, Q1 2026) posted Q1 2026 consolidated revenue of ₩129.1 billion (~$87.9 million), up 11.3%, with operating profit up 58.6%, driven by continued growth in non-respiratory syndromic diagnostic products and improved cost efficiency, following a Q4 2025 return to operating profitability.

MRR's Take: Seegene's non-respiratory syndromic PCR portfolio is a clear Star actively offsetting the structural decline in pandemic-era respiratory testing demand that once defined the company.

22. Wiener Laboratorios S.A.I.C.

Wiener Laboratorios S.A.I.C. is a privately held Argentine IVD manufacturer with no public financial disclosures; multiple independent Latin America IVD market studies consistently name it among the region's established local players, particularly in Argentina and Brazil (via its Labinbraz affiliate), competing alongside the global majors profiled above.

MRR's Take: With no disclosed financials, Wiener's position cannot be classified on this matrix; its consistent inclusion across multiple independent regional market studies indicates a durable, if unquantified, Cash Cow-type regional presence.

23. Wama Diagnóstica

Wama Diagnóstica is a privately held Brazilian IVD manufacturer, founded in 1991 and headquartered in São Carlos, Brazil, with no public financial disclosures; it is likewise consistently named across independent Latin America IVD market studies as an established regional player.

MRR's Take: As with Wiener, the absence of disclosed financials means Wama cannot be classified on this matrix; its long operating history and consistent regional-market inclusion suggest established, durable local share rather than a fast-growing or declining position.

Consolidated Growth-Share Matrix — In Vitro Diagnostics, 2026

The China pattern is this matrix's most striking finding: five separate companies — Bio-Rad, QuidelOrtho, QIAGEN, Sysmex, and Siemens Healthineers — independently cited China-specific weakness in 2026, ranging from pricing-reform impact to outright guidance cuts, while Agilent posted the opposite result, with China growth of 9% against a flat expectation. That divergence suggests the China effect is more company- and product-mix-specific than a uniform market-wide contraction.

Strategic Imperatives for 2026–2031

1. Oncology and molecular testing is decisively the sector's highest-growth category. Natera's 38% quarterly growth and string of 2026 regulatory approvals, alongside Illumina's accelerating clinical sequencing demand, both point to liquid biopsy and MRD testing as the clearest place where IVD growth is compounding fastest, well ahead of the broader market's 4.94% CAGR.
2. China requires product-line-specific strategy, not a single regional playbook. The same market that sharply cut QuidelOrtho's and Sysmex's guidance simultaneously delivered Agilent's strongest China quarter in memory — suggesting instrument and reagent mix, not blanket market exposure, determines outcomes there.
3. Portfolio-sharpening through targeted divestiture is a repeated 2026 pattern. BD's Waters spinoff, Thermo Fisher's microbiology divestiture, Revvity's China immunodiagnostics exit, and Werfen's distribution-business sale to Palex all represent the same underlying logic: shedding lower-margin or structurally disadvantaged segments to concentrate capital on higher-growth, higher-margin diagnostics categories.
4. Regulatory and reimbursement variables are increasingly explicit line items in company guidance. QIAGEN's disclosed $35 million QuantiFERON immigration-testing impact and Dexcom's CMS coverage-timing dependency both show companies now quantifying policy risk directly in their outlooks rather than treating it as unstated background uncertainty.

Outlook

With the underlying market forecast to grow at a steady but modest 4.94% CAGR toward roughly $127–133 billion by 2031, and disclosed performance across the 23 companies profiled ranging from Natera's 38% growth to QuidelOrtho's sharply cut guidance, the IVD sector in 2026 is best understood as two markets moving at very different speeds within one category. On the disclosed evidence, oncology- and molecular-testing specialists (Natera, Illumina, Exact Sciences) are capturing the clear majority of the category's genuine growth, while the diversified, instrument-heavy incumbents are working through a more mixed picture shaped heavily by China-specific and academic-funding dynamics that vary significantly by company and product mix rather than moving in lockstep.

This analysis draws on company-reported earnings releases, investor presentations, and public regulatory filings from bioMérieux, Abbott Laboratories, F. Hoffmann-La Roche (Roche Diagnostics), Siemens Healthineers, Danaher Corporation, Thermo Fisher Scientific, Becton Dickinson, Bio-Rad Laboratories, QIAGEN, Hologic, Natera, Seegene, Werfen, Wiener Laboratorios, Wama Diagnóstica, Sysmex Corporation, Agilent Technologies, Bruker Corporation, Dexcom, Exact Sciences, Illumina, QuidelOrtho Corporation, and Revvity, current through September 2026, together with the market-sizing framework of the Global In Vitro Diagnostics (IVD) Market Strategic Research Report.